Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5

Journal of Clinical Oncology

Volumn 33, Issue 7, 2015, Pages 723-731

  Fizazi, Karim ^a   Jones, Robert ^c   Oudard, Stephane ^b   Efstathiou, Eleni ^e   Saad, Fred ^g   De Wit, Ronald ^h   De Bono, Johann ^d   Cruz, Felipe Melo ⁱ   Fountzilas, George ^f   Ulys, Albertas ^k   Carcano, Flavio ^j   Agarwal, Neeraj ^l   Agus, David ^m   Bellmunt, Joaquim ^r   Petrylak, Daniel P ⁿ   Lee, Shih Yuan ^o   Webb, Iain J ^p   Tejura, Bindu ^o   Borgstein, Niels ^o   Dreicer, Robert ^q  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^f ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^g CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ FACULDADE DE MEDICINA DO ABC   (Brazil)

^j BARRETOS CANCER HOSPITAL   (Brazil)

^k VILNIUS UNIVERSITY   (Lithuania)

^l UNIVERSITY OF UTAH   (United States)

^m UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁿ YALE CANCER CENTER   (United States)

^o Takeda Pharmaceuticals International   (United States)

^p MILLENNIUM PHARMACEUTICALS INC   (United States)

^q LERNER RESEARCH INSTITUTE   (United States)

^r HOSPITAL DEL MAR   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; DOCETAXEL; LACTATE DEHYDROGENASE; ORTERONEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; NAPHTHALENE DERIVATIVE; TAXOID; TUMOR MARKER;

ADRENAL INSUFFICIENCY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; BRIEF PAIN INVENTORY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONFERENCE PAPER; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; GLEASON SCORE; HUMAN; HYPERTENSION; HYPOKALEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREATITIS; PATIENT HISTORY OF CHEMOTHERAPY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SPINAL CORD COMPRESSION; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; URINARY TRACT INFECTION; URINE RETENTION; UROSEPSIS; VERY ELDERLY; BLOOD; CANCER GRADING; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; EUROPE; KAPLAN MEIER METHOD; MIDDLE AGED; NORTH AMERICA; PAIN MEASUREMENT; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EUROPE; HUMANS; IMIDAZOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NAPHTHALENES; NEOPLASM GRADING; NORTH AMERICA; ODDS RATIO; PAIN MEASUREMENT; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84925006635     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.5119     Document Type: Conference Paper

References (28)

1. Huggins C, Hodges CV: Studies on prostatic cancer, I: The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22:232-240, 1972
2. Horwich A, Hugosson J, de Reijke T, et al: Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol 24:1141-1162, 2013
3. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997
4. Scher HI, Sawyers CL: Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23:8253-8261, 2005
5. Carver BS, Chapinski C, Wongvipat J, et al: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19:575-586, 2011
6. Fizazi K, Martinez LA, Sikes CR, et al: The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res 8:775-781, 2002
7. Grossmann ME, Huang H, Tindall DJ: Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93:1687-1697, 2001
8. Montgomery RB, Mostaghel EA, Vessella R, et al: Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 68: 4447-4454, 2008
9. Miller WL, Auchus RJ: The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 32:81-151, 2011
10. Stewart P: Chapter 14: The adrenal cortex, in Kronenberg HM, Melmed S, Polonsky KS, et al (eds): Williams Textbook of Endocrinology. St Louis, MO, Elsevier Saunders, 2013, pp 446-452
11. Ryan CJ, Smith MR, de Bono JS, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138-148, 2013
12. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
13. Fizazi K, Scher HI, Molina A, et al: Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983-992, 2012
14. Kluetz PG, Ning YM, Maher VE, et al: Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: US Food and Drug Administration drug approval summary. Clin Cancer Res 19:6650-6656, 2013
15. Kaku T, Hitaka T, Ojida A, et al: Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem 19:6383-6399, 2011
16. Yamaoka M, Hara T, Hitaka T, et al: Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol 129:115-128, 2012
17. Dreicer R, Maclean D, Suri A, et al: Phase I/II trial of orteronel (TAK-700) - an investigational 17,20-lyase inhibitor - in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 20:1335-1344, 2014
18. Hussain M, Corn PG, Michaelson MD, et al: Phase II study of single agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen. Clin Cancer Res 20:4218-4227, 2014
19. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
20. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008
21. Daut RL, Cleeland CS, Flanery RC: Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 17:197-210, 1983
22. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE), Version 4.02. http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE-4.02-2009-09-15-QuickReference-8.5x11.pdf
23. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012
24. de Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154, 2010
25. De Wit R, Fizazi K, Jinga V, et al: Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial). J Clin Oncol 32:325s, 2014 (suppl 15s; abstr 5008)
26. Small EJ, Schellhammer PF, Higano CS, et al: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089-3094, 2006
27. Saad ED, Buyse M: Overall survival: Patient outcome, therapeutic objective, clinical trial end point, or public health measure? J Clin Oncol 30:1750-1754, 2012
28. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010